PRESS RELEASE
News
-
-
-
-
-
PRESS RELEASE
Viscom AG feels the effects of investment restraint in the first quarter and makes a cautious start to the 2024 financial year
Viscom AG reports a challenging first quarter in 2024 due to investment restraint, with a significant decline in orders and revenue. The company remains cautiously optimistic for the rest of the year -
-
-
-
PRESS RELEASE
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases
OSE Immunotherapeutics and Boehringer Ingelheim expand partnership to develop first-in-class therapies for cancer and cardio-renal-metabolic diseases, aiming to address unmet patient needs -
PRESS RELEASE
OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements first-in-class dans le cancer et dans les maladies cardiovasculaires, rénales et métaboliques
OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements innovants dans le cancer et les maladies CVRM. Deux nouveaux projets first-in-class annoncés renforcent le portefeuille de Boehringer Ingelheim
